AP2015008803A0 - Methods for treating psoriasis using an anti-il-23antibody - Google Patents

Methods for treating psoriasis using an anti-il-23antibody

Info

Publication number: AP2015008803A0
Authority: AP; ARIPO
Prior art keywords: 23antibody; methods; treating psoriasis; psoriasis; treating
Prior art date: 2013-03-15

Application number

AP2015008803A

Inventor

Wei-Jian Pan

Wayne Tsuji

John P Gibbs

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-02-25

Publication date

2015-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2015008803(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-02-25 Application filed by Amgen Inc filed Critical Amgen Inc

2015-10-31 Publication of AP2015008803A0 publication Critical patent/AP2015008803A0/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)

AP2015008803A 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23antibody AP2015008803A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361789777P	2013-03-15	2013-03-15
PCT/US2014/018293 WO2014149425A1 (en)	2013-03-15	2014-02-25	Methods for treating psoriasis using an anti-il-23 antibody

Publications (1)

Publication Number	Publication Date
AP2015008803A0 true AP2015008803A0 (en)	2015-10-31

Family

ID=50336511

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2015008803A AP2015008803A0 (en)	2013-03-15	2014-02-25	Methods for treating psoriasis using an anti-il-23antibody

Country Status (17)

Country	Link
US (3)	US20160060337A1 (en)
EP (2)	EP2968488A1 (en)
JP (4)	JP2016517408A (en)
KR (1)	KR20150128858A (en)
CN (1)	CN105209064A (en)
AP (1)	AP2015008803A0 (en)
AU (3)	AU2014238148A1 (en)
CA (1)	CA2906382A1 (en)
CL (1)	CL2015002723A1 (en)
CR (1)	CR20150572A (en)
EA (1)	EA201591581A1 (en)
HK (1)	HK1219425A1 (en)
IL (2)	IL241342A0 (en)
PH (2)	PH12015502129A1 (en)
SG (2)	SG10201804954UA (en)
TN (1)	TN2015000403A1 (en)
WO (1)	WO2014149425A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2635601B1 (en)	2010-11-04	2016-07-20	Boehringer Ingelheim International GmbH	Anti-il-23 antibodies
WO2013165791A1 (en)	2012-05-03	2013-11-07	Boehringer Ingelheim International Gmbh	Anti-il-23p19 antibodies
EP3172339A1 (en)	2014-07-24	2017-05-31	Boehringer Ingelheim International GmbH	Biomarkers useful in the treatment of il-23a related diseases
US10059763B2 (en)	2014-09-03	2018-08-28	Boehringer Ingelheim International Gmbh	Compound targeting IL-23A and TNF-alpha and uses thereof
IL307578A (en) *	2015-02-04	2023-12-01	Boehringer Ingelheim Int	Methods for treating inflammatory diseases
US10765724B2 (en) *	2016-03-29	2020-09-08	Janssen Biotech, Inc.	Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
AU2017250583A1 (en) *	2016-04-15	2018-08-16	Boehringer Ingelheim International Gmbh	Methods of treating inflammatory diseases
JP7634474B2 (en) *	2018-07-18	2025-02-21	ヤンセンバイオテツク，インコーポレーテツド	Predictors of sustained response following treatment with anti-IL23 specific antibodies
KR20210091209A (en) *	2018-11-05	2021-07-21	머크 샤프 앤드 돔 코포레이션	Dosage regimen of anti-TIGIT antibodies for the treatment of cancer
EP3941934A4 (en) *	2019-03-18	2022-12-07	Janssen Biotech, Inc.	Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
CO4810232A1 (en)	1997-07-25	1999-06-30	Schering Corp	MAMMALIAN CYTOKINES AND THEIR CODING SEQUENCES
ES2410406T3 (en)	2005-06-30	2013-07-01	Janssen Biotech, Inc.	Anti-IL-23 antibodies, compositions, procedures and uses
EP1937721B1 (en)	2005-08-25	2010-07-28	Eli Lilly And Company	Anti-il-23 antibodies
US20070050011A1 (en)	2005-08-26	2007-03-01	Medlogics Device Corporation	Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
HUE032131T2 (en)	2005-08-31	2017-09-28	Merck Sharp & Dohme	Engineered anti-il-23 antibodies
AU2006330410A1 (en) *	2005-12-28	2007-07-05	Centocor, Inc.	Markers and methods for assessing and treating psoriasis and related disorders
EP3219328B1 (en)	2005-12-29	2020-06-17	Janssen Biotech, Inc.	Human anti-il-23 antibodies, compositions, method and uses
AU2007260787A1 (en)	2006-06-13	2007-12-21	Zymogenetics, Inc	IL-17 and IL-23 antagonists and methods of using the same
EP2064242A1 (en) *	2007-02-23	2009-06-03	Schering Corporation	Engineered anti-il-23p19 antibodies
ATE554791T1 (en)	2007-02-23	2012-05-15	Schering Corp	GENETICALLY ENGINEERED ANTI-IL-23P19 ANTIBODIES
AR068723A1 (en)	2007-10-05	2009-12-02	Glaxo Group Ltd	PROTEIN THAT JOINS ANTIGENS THAT JOINS HUMAN IL-23 AND ITS USES
WO2009082624A2 (en)	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US8557239B2 (en) *	2009-09-14	2013-10-15	Abbvie Inc.	Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
TWI461210B (en) *	2008-03-18	2014-11-21	Abbvie Inc	Methods for treating psoriasis
WO2010002776A2 (en)	2008-06-30	2010-01-07	Black & Decker Inc.	Cord protector for power tools
WO2010027766A1 (en)	2008-08-27	2010-03-11	Schering Corporation	Lyophilized formulatons of engineered anti-il-23p19 antibodies
WO2010115786A1 (en)	2009-04-01	2010-10-14	Glaxo Group Limited	Anti-il-23 immunoglobulins
WO2010142534A1 (en)	2009-05-27	2010-12-16	Ablynx Nv	Biparatopic protein constructs directed against il-23
JO3244B1 (en)	2009-10-26	2018-03-08	Amgen Inc	Proteins bind to human IL-23 antigens
WO2011088120A1 (en)	2010-01-15	2011-07-21	Amgen Inc.	Antibody formulation and therapeutic regimens
US9127057B2 (en)	2010-07-20	2015-09-08	Teva Pharmaceuticals Ausralia Pty Ltd	Anti-IL-23 heterodimer specific antibodies
CN103813804A (en) *	2010-10-06	2014-05-21	Abbvie公司	Methods for treating psoriasis
CN103154031A (en) *	2010-10-08	2013-06-12	诺华有限公司	Methods of treating psoriasis using il-17 antagonists
EP2635601B1 (en)	2010-11-04	2016-07-20	Boehringer Ingelheim International GmbH	Anti-il-23 antibodies

2014
- 2014-02-25 US US14/776,222 patent/US20160060337A1/en not_active Abandoned
- 2014-02-25 AP AP2015008803A patent/AP2015008803A0/en unknown
- 2014-02-25 JP JP2016500381A patent/JP2016517408A/en active Pending
- 2014-02-25 HK HK16107479.7A patent/HK1219425A1/en unknown
- 2014-02-25 EA EA201591581A patent/EA201591581A1/en unknown
- 2014-02-25 CA CA2906382A patent/CA2906382A1/en not_active Abandoned
- 2014-02-25 CN CN201480015797.0A patent/CN105209064A/en active Pending
- 2014-02-25 WO PCT/US2014/018293 patent/WO2014149425A1/en not_active Ceased
- 2014-02-25 EP EP14711352.6A patent/EP2968488A1/en not_active Withdrawn
- 2014-02-25 AU AU2014238148A patent/AU2014238148A1/en not_active Abandoned
- 2014-02-25 SG SG10201804954UA patent/SG10201804954UA/en unknown
- 2014-02-25 EP EP19206477.2A patent/EP3689369A1/en not_active Withdrawn
- 2014-02-25 SG SG11201507482UA patent/SG11201507482UA/en unknown
- 2014-02-25 KR KR1020157027833A patent/KR20150128858A/en not_active Ceased
2015
- 2015-09-09 TN TN2015000403A patent/TN2015000403A1/en unknown
- 2015-09-09 IL IL241342A patent/IL241342A0/en unknown
- 2015-09-15 CL CL2015002723A patent/CL2015002723A1/en unknown
- 2015-09-15 PH PH12015502129A patent/PH12015502129A1/en unknown
- 2015-10-15 CR CR20150572A patent/CR20150572A/en unknown
2019
- 2019-01-11 AU AU2019200206A patent/AU2019200206A1/en not_active Abandoned
- 2019-09-24 JP JP2019172758A patent/JP2020063237A/en active Pending
- 2019-10-10 US US16/598,714 patent/US20200277368A1/en not_active Abandoned
- 2019-11-28 PH PH12019502700A patent/PH12019502700A1/en unknown
2020
- 2020-06-03 IL IL275093A patent/IL275093A/en unknown
- 2020-11-18 AU AU2020270495A patent/AU2020270495A1/en not_active Abandoned
2021
- 2021-03-29 JP JP2021054632A patent/JP2021102644A/en active Pending
2022
- 2022-01-13 US US17/574,980 patent/US20220135668A1/en not_active Abandoned
- 2022-11-02 JP JP2022175999A patent/JP2023011815A/en not_active Withdrawn

Also Published As

Publication number	Publication date
CR20150572A (en)	2016-04-25
WO2014149425A1 (en)	2014-09-25
CL2015002723A1 (en)	2016-03-28
EP3689369A1 (en)	2020-08-05
US20220135668A1 (en)	2022-05-05
PH12019502700A1 (en)	2020-12-07
TN2015000403A1 (en)	2017-01-03
CN105209064A (en)	2015-12-30
AU2014238148A1 (en)	2015-10-08
EA201591581A1 (en)	2016-01-29
EP2968488A1 (en)	2016-01-20
SG10201804954UA (en)	2018-07-30
US20200277368A1 (en)	2020-09-03
JP2016517408A (en)	2016-06-16
JP2021102644A (en)	2021-07-15
SG11201507482UA (en)	2015-10-29
US20160060337A1 (en)	2016-03-03
KR20150128858A (en)	2015-11-18
PH12015502129A1 (en)	2016-01-25
IL275093A (en)	2020-07-30
IL241342A0 (en)	2015-11-30
JP2023011815A (en)	2023-01-24
AU2019200206A1 (en)	2019-01-31
HK1219425A1 (en)	2017-04-07
AU2020270495A1 (en)	2020-12-17
JP2020063237A (en)	2020-04-23
CA2906382A1 (en)	2014-09-25

Publication	Publication Date	Title
SG11201603050TA (en)	2016-05-30	Methods for treating cancers
GB201318983D0 (en)	2013-12-11	Radiotherapy apparatus
GB201309057D0 (en)	2013-07-03	Method
IL275093A (en)	2020-07-30	Methods for treating psoriasis using an anti-il-23 antibody
GB201309928D0 (en)	2013-07-17	Method
PT3016682T (en)	2020-05-20	Methods for treating cancer
EP3082841A4 (en)	2017-07-26	Methods for treating an animal
GB201313249D0 (en)	2013-09-11	Method
GB201301857D0 (en)	2013-03-20	Method
GB201300409D0 (en)	2013-02-27	Method
GB201309654D0 (en)	2013-07-17	Method
GB201305714D0 (en)	2013-05-15	Method
GB201301233D0 (en)	2013-03-06	Method
GB201311385D0 (en)	2013-08-14	Method
GB201301094D0 (en)	2013-03-06	Method
PT2836176T (en)	2017-10-27	Technique for treating presbyopia
GB201312609D0 (en)	2013-08-28	Method
GB201314507D0 (en)	2013-09-25	Method for increasing dipole work
GB201311389D0 (en)	2013-08-14	Method
GB201322764D0 (en)	2014-02-05	Treating places
GB201313412D0 (en)	2013-09-11	Method
GB201313416D0 (en)	2013-09-11	Method
GB201312397D0 (en)	2013-08-21	Method
GB201311392D0 (en)	2013-08-14	Method
GB201311394D0 (en)	2013-08-14	Method